EUCTR2008-003568-20-IE进行中（未招募）不适用
Renin Genotype and Response to Renin Angiotensin System Blockade.
Prof Alice Stanton0 个研究点开始时间: 2008年6月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female outpatients
- •Age greater than 18 years.
- •Written informed consent provided.
- •Patients with essential hypertension who are either antihypertensive treatment naïve, or taking a maximum of two antihypertensive agents – beta-blockers and alpha-blockers already prescribed for indications other than hypertension, at a dose which will not change during the study, may be continued.
- •Baseline mean 24-hour systolic pressure > 130 mm Hg, and < 160 mm Hg, either on no treatment or on amlodipine 10 mg daily.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Age less than 18 years old.
- •Pregnancy, women who are breast feeding, or with childbearing potential without using a medically accepted method of contraception.
- •Presence of any significant acute or chronic illness. In particular participants must not have a history of an acute cardiovascular morbid event within the last 3 months. They must not have suffered with malignant hypertension or congestive heart failure. They must not have a terminal illness.
- •Significant baseline electrolyte, serum creatinine or creatinine clearance abnormalities (potassium > 5.5 mmol/l, or serum creatinine > 150 micromol/l, or creatinine clearance < 30mls/minute as assessed by Cockcroft’s formula)
- •oMen = (140 - age) X weight (kg) / (0.814 X creatinine level (micromol/l)
- •oWomen = 0.85 X [(140 - age) X weight (kg) / (0.814 X creatinine level (micromol/l)]
- •Known secondary hypertension
- •Requirement for any specific antihypertensive drug therapy.
- •Contra-indications to any of the study drugs.
- •Participation in any other studies involving investigational or marketed products within one month prior to entry into this study or concomitantly with this study.
- •Participants that are unlikely to comply well with study treatments or with the scheduled visits.
- •Participants with a history of alcohol or drug abuse, psychosis, antagonistic personality, or any emotional or intellectual problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.
研究者
相似试验
招募中
不适用
On the Role of The (Pro)Renin-Angiotensin System in Preeclampsiapreeclampsiatoxicosis of pregnancy10026908NL-OMON32502Erasmus MC, Universitair Medisch Centrum Rotterdam120
撤回
不适用
Renin-Angiotensin System and Other Markers in Strawberry Birthmarks in infants and young children with growing problematic haemangiomasInfantile HaemangiomaSkin - Dermatological conditionsACTRN12612001227886Hutt Valley DHB40
暂停
不适用
The Effect of Renin-Angiotensin System Inhibition on Aortic Dilatation Rate in Patients with Coarctation of the Aorta.Aortic coarctationnarrowing of the aorta10010394NL-OMON48859niversitair Medisch Centrum Utrecht80
已完成
不适用
The Renin Angiotensin System in Essential HypertensioCardiovascular: Essential hypertensionCirculatory SystemEssential (primary) hypertensionISRCTN12415112Record Provided by the NHSTCT Register - 2006 Update - Department of Health22
已完成
不适用
Influence of angiotensin receptor blocker on renin-angiotensin-aldosterone system after cardiac surgeryJPRN-UMIN000001463Sekino Hospital200